Zusammenfassung
Durchblutungsfördernde Mittel werden bei peripheren und zerebralen Durchblutungsstörungen eingesetzt. Die Mehrzahl der Präparate ist nur noch für die Anwendung bei peripheren arteriellen Durchblutungsstörungen zugelassen. Diese indikative Abgrenzung ist vor allem dadurch entstanden, daß zahlreiche Herstellerfirmen ihre Präparate ab 1996 zusammen mit den Nootropika in eine neu geschaffene Indikationsgruppe „Antidementiva“ umgruppiert haben (s. ).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Adhoute G., Andreassian B., Boccalon H., Cloarec M., Di Maria G. et al. (1990): Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. J. Cardiovasc. Pharmacol. 16(Suppl. 3): S75–S80.
Adhoute G., Bacourt F., Barrai M., Cardon J.M., Chevalier J.M. et al. (1986): Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using naftidrofuryl tablets 200 mg. Angiology 37: 160–167.
Arzneimittelkommission der Deutschen Apotheker (1995): Naftidrofuryl Infusionslösung. Pharmazeut. Ztg. 140: 2222.
Barradell L.B., Brogden R.N. (1996): Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging 8: 299–322.
Bauer U. (1984): 6-Month double-blind randomised clinical trial of ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. Arzneim. Forsch. 34: 716–720.
Bollinger A., Frei Ch. (1977): Double-blind study of pentoxifylline against placebo in patients with intermittent claudication. Pharmatherapeutica 1: 557–563.
Clifford P.C., Davies P.W., Hayne J.A., Baird R.N. (1980): Intermittent claudication: is a supervised exercise class worth while? Brit. Med. J. 280: 1503–1505.
Clyne C.A.C., Galland R.B., Fox M.J., Gustave R., Jantet G.H., Jamieson C.W. (1980): A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication. Br. J. Surg. 67: 347–348.
Creasy T.S., McMillan P.J., Fletcher E.W.L., Collin J., Morris RJ. (1990): Is percutaneous transluminal angioplasty better than exercise for claudication?—Preliminary results from a prospective randomised trial. Eur. J. Vasc. Surg. 4: 135–140.
Cummings D.M., Ballas S.K., Ellison M.J. (1992): Lack of effect of pentoxifylline on red blood cell deformability. J. Clin. Pharmacol. 32: 1050–1053.
Dahllöf A.-G., Holm J., Scherstén T., Sivertsson R. (1976): Peripheral arterial insufficiency. Effect of physical training on walking tolerance, calf blood flow, and blood flow resistance. Scand. J. Rehab. Med. 8: 19–26.
Dettori A.G., Pini M., Moratti A., Paolicelli M., Basevi P. et al. (1989): Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. Angiology 40: 237–248.
Di Perri T., Carandente O., Vittoria A., Guerrini M., Messsa G.L. (1984): Studies of the clinical pharmacology and therapeutic efficacy of pentoxifylline in peripheral obstructive arterial disease. Angiology 35: 427–435.
Donaldson D.R., Hall T.J., Kester R.C., Ramsden C.W., Wiggins P.A. (1984): Does oxpentifylline (’Trental’) have a place in the treatment of intermittent claudication? Curr. Med. Res. Opin. 9: 35–40.
Drabaek H., Petersen J.R., Winberg N., Hansen K.F., Mehlsen J. (1996): The effect of Ginkgo biloba extract in patients with intermittent claudication. Ugeskr. Laeger 158: 3928–3931.
Ekroth R., Dahllöf A.-G., Gundevall B., Holm J., Scherstén T. (1978): Physical training of patients with intermittent claudication: indications, methods, and results. Surgery 84: 640–643.
Ernst E., Kollár L., Resch K.L. (1992): Does pentoxifylline prolong the walking distance in exercised claudicants? A placebo-controlled double-blind trial. Angiology 43: 121–125.
Ernst E. (1994): Pentoxifylline for intermittent claudication. A critical review. Angiology 45: 339–345.
Gallus A.S., Morley A.A., Dupont P., Walsh H., Gleadow F. et al. (1985): Intermittent claudication: a double-blind study crossover trial of pentoxifylline. Aust. N. Z. J. Med. 15: 402–409.
Girolami B., Bernardi E., Prins M.H., Wouter ten Cate J., Hettiarachchi R. et al. (1999): Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl. Arch. Intern. Med. 159: 337–345.
Heidrich H., Allenberg J., Cachovan M., Creutzig A., Diehm C. et al. (1992): Prüfrichtlinien für Therapiestudien im Fontaine-Stadium II-IV bei peripher-arterieller Verschlußkrankheit. Vasa 21: 333–337.
Hiatt W.R., Regensteiner J.G., Hargarten M.E., Wolfel E.E., Brass E.P. (1990): Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 81: 602–609.
Hiatt W.R., Wolfel E.E., Meier R.H., Regensteiner J.G. (1994): Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Circulation 90: 1866–1874.
Housley E. (1988): Treating claudication in five words. Brit. Med. J. 296: 1483–1484.
Jonason T., Jonzon B., Ringqvist I., Öman-Rydberg A. (1979): Effect of physical training on different categories of patients with intermittent claudication. Acta Med. Scand. 206: 253–258.
Karnik R., Valentin A., Stöllberger C., Slany J. (1988): Effects of naftidrofuryl in patients with intermittent claudication. Angiology 39: 234–240.
Kiesewetter H., Blume J., Jung F., Gerhards M., Leipnitz G. (1987): Gehtraining und medikamentöse Therapie bei der peripheren arteriellen Verschlußkrankheit. Randomisierte, prospektive, placebo-kontrollierte Doppelblindstudie. Dtsch. Med. Wochenschr. 112: 873–878.
Kriessmann A., Neiss A. (1988): Klinischer Wirksamkeitsnachweis von Naftidrofuryl bei Claudicatio intermittens. VASA (Suppl. 24): 27–32.
Larsen O.A., Lassen N.A. (1966): Effect of daily muscular exercise in patients with intermittent claudication. Lancet 2: 1093–1096.
Lindgärde F., Jelnes R., Björkman H., Adielsson G., Kjellström T. et al. (1989): Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation 80: 1549–1556.
Lundgren F., Dahllöf A.-G., Lundholm K., Scherstén T., Volkmann R. (1989): Intermittent claudication—surgical reconstruction or physical training? Ann. Surg. 209: 346–355.
Mannarino E., Pasqualini L., Innocente S., Scricciolo V, Rignanese A., Ciuffetti G. (1991): Physical training and antiplatelet treatment in stage II peripheral arterial occlusive disease: alone or combined? Angiology 42: 513–521}.
Moody A.P., Al-Khaffaf H.S., Lehert P., Harris P.L., Charlesworth D. (1994): An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J. Cardiovasc. Pharmacol. 23(Suppl. 3): S44–S47.
Norwegian Pentoxifylline Multicenter Trial Group (1996): Efficacy and clinical tolerance of parenteral pentoxifylline in the treatment of critical lower limb ischemia. Int. Angiol. 15: 75–80.
Pedersen T.R., Kjekshus J., Pyörälä K., Olsson A.G., Cook T.J. et al. (1998): Effect of Simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am. J. Cardiol. 81: 333–335.
Porter J.M., Cutler B.S., Lee B.Y., Reich Th., Reichle F.A. et al. (1982): Pentoxifylline efficacy in the treatment of intermittent claudication. Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am. Heart J. 104: 66–72.
Quick C.R., Cotton L.T. (1982): The measured effect of stopping smoking on intermittent claudication. Brit. J. Surg. 69 (Suppl.): S24–S26.
Radack K., Wyderski R.J. (1990): Conservative management of intermittent claudication. Ann. Intern. Med. 113: 135–146.
Reilly D.T., Quinton D.N., Barrie W.W. (1987): A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheological effects. New Zeal. Med. J. 100: 445–447.
Rieger H., Hossmann V. (1998): Medikamentöse Durchblutungssteigerung bei chronischer peripherer arterieller Verschlußkrankheit. In: Rieger H., Schoop W. (Hrsg.): Lehrbuch der Angiologie. Springer Verlag Berlin Heidelberg New York, S. 239–252.
Roekaerts F., Deleers L. (1984): Trental® 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration. Angiology 35: 396–406.
Rudofsky G., Haussler K.E, Kunkel H.P., Schneider-May H., Spengel E, Symann O., Werner H.-J. (1989): Intravenous treatment of chronic peripheral occlusive arterial disease: a double-blind, placebo-controlled, randomized, multicenter trial of pentoxifylline. Angiology 40: 639–649.
Scheffler A., Rieger H. (1999): Arterielle Durchblutungsstörungen. In: Paumgartner G. (Hrsg.): Therapie innerer Krankheiten. 9. Aufl., Springer Verlag Berlin Heidelberg New York, S. 257–273.
Scheffler P., de la Hamette D., Gross J., Mueller H., Schieffer H. (1994): Intensive vascular training in stage llb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin El or intravenous pentoxifylline during training. Circulation 90: 818–822.
Schoop W., Breddin K., Diehm C., Gruß J., Held K. et al. (1996): Klinische Prüfung mit Ginkgo biloba-Spezialextrakt Egb 761 bei Patienten mit peripherer arterieller Verschlußkrankheit im Stadium 11b nach Fontaine im Vergleich zu Placebo. Posterpublikation, Jahreskongress der Schweizerischen Gesellschaft für Angiologie 1.-2.11.1996.
Strano A., Davi G., Avellone G., Novo S., Pinto A. (1984): Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 35: 459–466.
Transparenzkommission (1983): Transparenzliste für das Teilgebiet periphere arterielle Durchblutungsstörungen. Bundesanzeiger Nr. 169 vom 9.9.1983.
Trübestein G., Böhme H., Heidrich H., Heinrich F., Hirche H., Maass U. et al. (1984): Naftidrofuryl in chronic arterial disease. Results of a controlled multicenter study. Angiology 35: 701–708.
Völker D. (1983): Treatment of arteriopathies with pentoxifylline (Trental 400): results of a double-blind study. Pharmatherapeutica 3(suppl. 1): 136–142.
Walker G.A., MacMannaford J.C. (1995): A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Fundam. Clin. Pharmacol. 9: 387–394.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2001). Durchblutungsfördernde Mittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2000. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56832-9_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-56832-9_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-67573-0
Online ISBN: 978-3-642-56832-9
eBook Packages: Springer Book Archive